CA3174790A1 - Bi- and monocyclic nucleoside analogs for treatment of hepatitis e - Google Patents
Bi- and monocyclic nucleoside analogs for treatment of hepatitis e Download PDFInfo
- Publication number
- CA3174790A1 CA3174790A1 CA3174790A CA3174790A CA3174790A1 CA 3174790 A1 CA3174790 A1 CA 3174790A1 CA 3174790 A CA3174790 A CA 3174790A CA 3174790 A CA3174790 A CA 3174790A CA 3174790 A1 CA3174790 A1 CA 3174790A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- compounds
- mmol
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169480 | 2020-04-14 | ||
| EP20169480.9 | 2020-04-14 | ||
| PCT/EP2021/059504 WO2021209419A1 (en) | 2020-04-14 | 2021-04-13 | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174790A1 true CA3174790A1 (en) | 2021-10-21 |
Family
ID=70289599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174790A Pending CA3174790A1 (en) | 2020-04-14 | 2021-04-13 | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086592A2 (en) * | 2022-10-17 | 2024-04-25 | Emory Unversity | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2025014360A1 (en) * | 2023-07-07 | 2025-01-16 | Erasmus University Medical Center Rotterdam | Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952714T3 (es) * | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| US9603864B2 (en) * | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610597QA (en) * | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2017210438A1 (en) * | 2016-06-03 | 2017-12-07 | Gilead Pharmasset Llc | Methods of treating hepatitis e viral infection |
-
2021
- 2021-04-13 KR KR1020227039015A patent/KR20230002592A/ko active Pending
- 2021-04-13 PE PE2022002242A patent/PE20230386A1/es unknown
- 2021-04-13 WO PCT/EP2021/059504 patent/WO2021209419A1/en not_active Ceased
- 2021-04-13 CN CN202180028212.9A patent/CN115515603A/zh active Pending
- 2021-04-13 AU AU2021255809A patent/AU2021255809B2/en active Active
- 2021-04-13 EP EP21716786.5A patent/EP4135715B1/en active Active
- 2021-04-13 CA CA3174790A patent/CA3174790A1/en active Pending
- 2021-04-13 JP JP2022562424A patent/JP2023522615A/ja active Pending
- 2021-04-13 AR ARP210100979A patent/AR121836A1/es unknown
- 2021-04-13 PH PH1/2022/552679A patent/PH12022552679A1/en unknown
- 2021-04-13 UY UY0001039172A patent/UY39172A/es unknown
- 2021-04-13 ES ES21716786T patent/ES2982564T3/es active Active
- 2021-04-13 MX MX2022012904A patent/MX2022012904A/es unknown
- 2021-04-13 BR BR112022020825A patent/BR112022020825A2/pt unknown
-
2022
- 2022-10-12 CL CL2022002804A patent/CL2022002804A1/es unknown
-
2026
- 2026-03-11 JP JP2026038584A patent/JP2026120528A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230310481A1 (en) | 2023-10-05 |
| EP4135715A1 (en) | 2023-02-22 |
| CL2022002804A1 (es) | 2023-03-31 |
| AU2021255809B2 (en) | 2026-08-06 |
| CN115515603A (zh) | 2022-12-23 |
| PH12022552679A1 (en) | 2024-04-22 |
| BR112022020825A2 (pt) | 2022-11-29 |
| EP4135715B1 (en) | 2024-05-08 |
| ES2982564T3 (es) | 2024-10-16 |
| MX2022012904A (es) | 2023-01-24 |
| AU2021255809A1 (en) | 2022-12-15 |
| PE20230386A1 (es) | 2023-03-06 |
| UY39172A (es) | 2021-10-29 |
| EP4135715C0 (en) | 2024-05-08 |
| WO2021209419A1 (en) | 2021-10-21 |
| AR121836A1 (es) | 2022-07-13 |
| KR20230002592A (ko) | 2023-01-05 |
| JP2023522615A (ja) | 2023-05-31 |
| JP2026120528A (ja) | 2026-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116751164B (zh) | 蛋白酶抑制剂、其制备和用途 | |
| KR102453808B1 (ko) | 필로비리다에 바이러스 감염을 치료하는 방법 | |
| CN101835780B (zh) | 用于治疗病毒感染诸如肝炎的咪唑并[1,2-a]吡嗪化合物 | |
| ES2623287T3 (es) | Derivado de nucleósido altamente activo para el tratamiento del VHC | |
| CA2899763C (en) | Nucleoside phosphoramidate compound and use thereof | |
| CN106928206A (zh) | 醛基类化合物及其制法和用途 | |
| SG181797A1 (en) | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors | |
| CN115087653A (zh) | 一种醛基类化合物的药物用途 | |
| TW201021798A (en) | Amide acetate derivative having inhibitory activity on endothelial lipase | |
| AU2008257158A1 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
| CN110105348A (zh) | 新型迈克尔受体类肠病毒71型抑制剂的制备及用途 | |
| EP4135715B1 (en) | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e | |
| CN116102553A (zh) | 一种芳香稠环亚胺类化合物及其制备方法和应用 | |
| US20040198777A1 (en) | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto | |
| CN107033149A (zh) | 一种新型dpp‑4 酶抑制剂及其制备和应用 | |
| HK40088561B (en) | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e | |
| HK40088561A (en) | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e | |
| OA21046A (en) | BI- and monocyclic nucleoside analogs for treatment of hepatitis E. | |
| CA3174825A1 (en) | Spirocyclic nucleoside analogues for the treatment of hepatitis e | |
| CA3174637A1 (en) | Alkynyl nucleoside analogs for treatment of hepatitis e | |
| HK40085931A (en) | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e | |
| WO2019233366A1 (zh) | 选择性a 2a受体拮抗剂 | |
| CN103936740B (zh) | 黄嘌呤衍生物 | |
| CN110981887A (zh) | 一类二氢青蒿素类化合物及其制备方法和医用用途 | |
| ITMI951793A1 (it) | Derivati di tiazina o di tiazepina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250325 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250428 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250520 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260625 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260716 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260716 |